COVID19 protein-protein wars: designing agents to block infection
The robustness, low cost and ease of production of monobodies and nanobodies make them attractive therapeutic candidates for COVID19. High stability solves the need for cold-chain storage, and offers other routes of administration such as aerosols, which could be attractive for respiratory diseases.